Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Zacks Research raised their FY2024 earnings per share estimates for Gilead Sciences in a note issued to investors on Wednesday, November 20th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earnings per share of $4.26 for the year, up from their prior estimate of $3.73. The consensus estimate for Gilead Sciences' current full-year earnings is $4.38 per share. Zacks Research also issued estimates for Gilead Sciences' Q4 2024 earnings at $1.55 EPS, Q1 2025 earnings at $1.62 EPS, Q3 2025 earnings at $1.87 EPS, Q4 2025 earnings at $1.70 EPS, FY2025 earnings at $6.91 EPS, Q1 2026 earnings at $1.55 EPS, Q2 2026 earnings at $1.75 EPS and FY2026 earnings at $7.44 EPS.
Several other equities research analysts have also weighed in on the company. Mizuho lifted their price target on Gilead Sciences from $90.00 to $100.00 and gave the company an "outperform" rating in a research report on Thursday. Leerink Partnrs raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 21st. Truist Financial increased their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a research note on Friday, November 8th. BMO Capital Markets boosted their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Finally, Daiwa America raised shares of Gilead Sciences to a "hold" rating in a research note on Monday, November 18th. Twelve research analysts have rated the stock with a hold rating, eleven have given a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $95.41.
Check Out Our Latest Stock Analysis on GILD
Shares of Gilead Sciences stock opened at $90.19 on Monday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $98.90. The company has a market cap of $112.40 billion, a P/E ratio of 1,002.11, a PEG ratio of 2.78 and a beta of 0.17. The company's fifty day simple moving average is $87.43 and its two-hundred day simple moving average is $76.95.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.29 earnings per share.
Institutional investors have recently bought and sold shares of the business. Manning & Napier Advisors LLC purchased a new stake in Gilead Sciences during the 2nd quarter valued at $25,328,000. Legal & General Group Plc raised its stake in shares of Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock valued at $851,743,000 after acquiring an additional 93,068 shares during the period. IRON Financial LLC bought a new stake in shares of Gilead Sciences in the 3rd quarter worth about $830,000. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Gilead Sciences by 13.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company's stock worth $19,630,000 after purchasing an additional 33,162 shares during the period. Finally, Cetera Investment Advisers grew its holdings in Gilead Sciences by 127.6% during the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company's stock valued at $15,668,000 after purchasing an additional 119,909 shares during the last quarter. Institutional investors own 83.67% of the company's stock.
In other news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares of the company's stock, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now directly owns 100,189 shares of the company's stock, valued at approximately $8,398,843.87. The trade was a 1.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 56,947 shares of company stock valued at $4,968,674 over the last ninety days. 0.16% of the stock is currently owned by company insiders.
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.42%. Gilead Sciences's payout ratio is presently 3,422.22%.
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.